iRhythm Launches $100M Accelerated Share Buyback Under $200M Program
IRTC is trading near its 52-week low of $82.85 (9.4% above the low).
Summary
iRhythm signed a $100M accelerated share repurchase agreement with JPMorgan Chase Bank, putting half of its newly authorized $200M buyback to work immediately. The board approved the $200M authorization on November 10 and formalized it in an 8-K on November 12; this ASR is the first actual execution against it. An ASR means the company hands the money to a bank and typically retires a large chunk of shares up front, so the buyback is real rather than a shelf announcement. At a roughly $3B market cap, $100M is a meaningful commitment of capital and a management vote of confidence after the stock absorbed a Q3 GAAP loss driven by a $49.8M litigation settlement charge and a Zio MCT FDA submission pushed into 2027.
At the time of this announcement, IRTC was trading at $90.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $82.85 to $192.47. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.